Overview
- AbbVie agreed to buy Apogee Therapeutics for $135.11 per share, valuing the company at roughly $10.9 billion and implying about a 49.5% premium to pre-announcement trading.
- The deal triggered a roughly 46% one-day jump in Apogee’s stock and lifted AbbVie shares, which closed higher in the sessions after the announcement.
- AbbVie is acquiring a clinical-stage IL-13 immunology asset aimed at atopic dermatitis and asthma, a move intended to diversify growth beyond Humira and supplement Skyrizi and Rinvoq.
- Analysts have largely reacted positively, with firms such as Canaccord and Wells Fargo updating models or maintaining bullish ratings, while noting that the asset’s value depends on later-stage trial results and approvals.
- The transaction will be financed mainly with debt, is expected to close in the third quarter of 2026 pending approvals, and creates competitive pressure in the immunology market that could affect rivals and patients’ future treatment options.